CoChat

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1

Open access
Hassounah, Said A., Alikhani, Ahmad, Oliveira, Maureen, Bharaj, Simrat, Ibanescu, Ruxandra-Ilinca, Osman, Nathan, Xu, Hong-Tao, Brenner, Bluma G., Mesplède, Thibault, Wainberg, Mark A. · 2017 · Antimicrobial Agents and Chemotherapy

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Animal models are essential to study novel antiretroviral drugs, resistance-associated mutations (RAMs), and treatment strategies. Bictegravir (BIC) is a novel potent integrase strand transfer inhibitor (INSTI) that has shown promising results against HIV-1 infection in vitro and in vivo and against clinical isolates with resistance against INSTIs. BIC has a higher genetic barrier to the development of resistance than two clinically approved INSTIs, termed raltegravir and elvitegravir. Another clinically approved INSTI, dolutegravir (DTG) also possesses a high genetic barrier to resistance, while a fourth compound, termed cabotegravir (CAB), is currently in late phases of clinical development. Here we report the susceptibilities of simian immunodeficiency virus (SIV) and HIV-1 integrase (IN) mutants containing various RAMs to BIC, CAB, and DTG. BIC potently inhibited SIV and HIV-1 in single cycle infection with 50% effective concentrations (EC 50 s) in the low nM range. In single cycle SIV infections, none of the E92Q, T97A, Y143R, or N155H substitutions had a significant effect on susceptibility to BIC (≤4-fold increase in EC 50 ), whereas G118R and R263K conferred ∼14-fold and ∼6-fold increases in EC 50 , respectively. In both single and multiple rounds of HIV-1 infections, BIC remained active against the Y143R, N155H, R263K, R263K/M50I, and R263K/E138K mutants (≤4-fold increase in EC 50 ). In multiple rounds of infection, the G140S/Q148H combination of substitutions decreased HIV-1 susceptibility to BIC 4.8-fold compared to 16.8- and 7.4-fold for CAB and DTG, respectively. BIC possesses an excellent resistance profile in regard to HIV and SIV and could be useful in nonhuman primate models of HIV infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.01695-17

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 52 · Cited by 40

Metadata

Authors
Hassounah, S. A., Alikhani, A., Oliveira, M., Bharaj, S., Ibanescu, R.-I., Osman, N., Xu, H.-T., Brenner, B. G., Mesplède, T., & Wainberg, M. A.
Affiliations
  • Lady Davis Institute for Medical Research (CA)
  • McGill University AIDS Centre, Lady Davis Institute for Medical Research, Montréal, Québec, Canada
Venue
Antimicrobial Agents and Chemotherapy
Published
2017-12
Volume
61
Issue
12
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2756332356
Cited by
40
References
52
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 7 · 2021: 2 · 2020: 10 · 2019: 5 · 2018: 8
FWCI
4.84
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Gouvernement du Canada | Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
bictegravir, cabotegravir, dolutegravir, integrase strand transfer inhibitors, HIV-1, SIVmac239, integrase resistance mutations, antiviral susceptibility, resistance barrier, integrase mutants, nonhuman primate model
MeSH terms
Raltegravir Potassium, Dolutegravir, Amides, HeLa Cells, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Microbial Sensitivity Tests, Mutation, Oxazines, Piperazines, Pyridones, Virus Replication, Simian Immunodeficiency Virus, HIV-1, Mutagenesis, Site-Directed, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Drug Resistance, Viral, Diketopiperazines, HEK293 Cells, Reverse Genetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1. https://app.cochat.ai/papers/10.1128/aac.01695-17
The paper
Hassounah, S. A., Alikhani, A., Oliveira, M., Bharaj, S., Ibanescu, R.-I., Osman, N., Xu, H.-T., Brenner, B. G., Mesplède, T., & Wainberg, M. A. (2017). Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01695-17

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.